Paratek Pharmaceuticals Inc (PRTK.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2014||Chairman of the Board, Chief Executive Officer|
|58||2017||President, Chief Operating Officer, Chief Medical Officer, Director|
|45||2014||Chief Financial Officer|
|56||2015||Senior Vice President, General Counsel, Corporate Secretary|
|2017||Senior Vice President - Business Development|
- BRIEF-Paratek Pharmaceuticals Files For Mixed Shelf Offering Of Up To $250 Mln
- BRIEF-Paratek Pharmaceuticals Q3 loss per share $0.77
- BRIEF-Paratek Pharmaceuticals to report Q3 results on Nov 8
- BRIEF-Consistent efficacy and safety profile observed in new analyses of OASIS-1 phase 3 study of omadacycline
- BRIEF-Paratek Pharma antibiotic granted additional qualified infectious disease product designation by FDA